Comparative Pharmacology
Head-to-head clinical analysis: DARVON versus ZIPAN 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVON versus ZIPAN 25.
DARVON vs ZIPAN-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a mu-opioid receptor agonist that inhibits ascending pain pathways by binding to opioid receptors in the CNS, altering pain perception. It also has weak local anesthetic effects.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by blocking serotonin reuptake into presynaptic neurons.
Propoxyphene hydrochloride (Darvon) for moderate to severe pain: 65 mg orally every 4 hours as needed; maximum 390 mg/day.
25 mg orally twice daily
None Documented
None Documented
6-12 hours (parent drug); norpropoxyphene half-life 30-36 hours, accumulates with repeated dosing, increasing risk of toxicity.
Terminal elimination half-life: 6-8 hours in adults; may be prolonged (up to 12 hours) in elderly or patients with renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism to norpropoxyphene, then renal excretion of metabolites; <20% excreted unchanged in urine; minor biliary/fecal elimination.
Primarily renal excretion of unchanged drug (70-80%); fecal elimination accounts for 15-20% via biliary excretion; less than 5% as metabolites.
Category C
Category C
Opioid Analgesic
Opioid Analgesic